Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Expanded Access Program for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic, for the Treatment of Serious Infections Caused by Staphylococcus Aureus.

Trial Profile

Expanded Access Program for AB-SA01, an Investigational Anti-Staphylococcus Aureus Bacteriophage Therapeutic, for the Treatment of Serious Infections Caused by Staphylococcus Aureus.

Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 08 Oct 2018

At a glance

  • Drugs AB SA01 (Primary)
  • Indications Staphylococcal infections
  • Focus Expanded access; Therapeutic Use
  • Sponsors AmpliPhi Biosciences Corporation
  • Most Recent Events

    • 08 Oct 2018 According to an AmpliPhi Biosciences media release, the treatment was conducted under emergency protocols per the Australian Therapeutic Goods Administration's (TGA) Special Access Scheme (SAS).
    • 08 Oct 2018 According to an AmpliPhi Biosciences media release, data from this study were presented at the IDWeek 2018 Conference.
    • 08 Oct 2018 Results presented in an AmpliPhi Biosciences Corporation media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top